Analysts Maintain Bullish Stance on HUTCHMED (China) with Buy Ratings and Price Targets Above HK$32
Key Insights
UBS maintained a Buy rating on HUTCHMED (China) (search) with a price target of HK$34.10, while shares closed at HK$17.60 on July 2.
Huatai Securities also reiterated a Buy rating with a price target of HK$32.82, with shares closing at HK$17.71.
The overall analyst consensus rates HUTCHMED (China) (search) as a Moderate Buy, with average price targets ranging from HK$266.82 to HK$278.12.
Analyst firms continue to express confidence in HUTCHMED (China) (search) (HCM), with two major securities firms reaffirming their Buy ratings on the pharmaceutical company in recent reports.
UBS maintained its Buy rating on HUTCHMED (China) (search) in a report released on July 2, setting a price target of HK$34.10. The company's shares closed at HK$17.60 on that day, suggesting significant upside potential based on the firm's valuation. The stock has traded within a one-year range of HK$15.57 to HK$30.75, with an average daily trading volume of approximately 4.4 million shares.
In a separate report, Huatai Securities also stuck to its Buy rating on HUTCHMED (China) (search), establishing a price target of HK$32.82. At the time of that report, shares closed at HK$17.71.
The broader analyst community reflects a Moderate Buy consensus rating for HUTCHMED (China) (search). According to the UBS report, the average analyst price target stands at HK$266.82, while the Huatai Securities report cites a consensus average price target of HK$278.12.
From a financial perspective, HUTCHMED (China) (search) currently holds a market capitalization of approximately HK$15.67 billion and trades at a price-to-earnings (P/E) ratio of 4.15, as noted in the Huatai Securities coverage.
The consistent Buy ratings from multiple analyst firms underscore a positive outlook on HUTCHMED (China) (search)'s valuation and future prospects within the pharmaceutical sector.